ReviewMicroorganisms2026
Probiotic and Dietary Supplements Intervention in Age-Related Neurodegenerative Disorders.
Review in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bile acids in Alzheimer's disease: a double-edged sword in gut-liver-brain signaling and neurodegeneration.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Canagliflozin attenuates Parkinson's disease and is associated with modulation of gut-inflammasome-brain axis in rats.Inflammopharmacology · 2026Article
- Microbiota-mitochondria axis in neurodegenerative disorders and retinal dysfunction: mechanisms and emerging therapeutic opportunities.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and mild cognitive impairment, represent a growing global health challenge. The present medicines offer only symptomatic alleviation with poor disease-modifying efficacy. Increasing data suggests that the gut-brain axis and dietary health are measurable contributions to cognitive impairment as we age. This review first focused on the mechanistic link between gut dysbiosis and neurodegeneration. Furthermore, the review discusses preclinical and clinical research that show how probiotics and dietary supplements improve brain function in the elderly using supplemental therapy methods. It also indicates that randomized clinical studies and meta-analyses suggest that probiotics and particular nutritional supplements provide modest but consistent cognitive advantages, which are most noticeable when patients receive therapy at the initial stage of their disease development. These advantages might originate from the combined impact of gut microbiota, immunological signaling, and neuroprotective pathways, rather than specific targeted approaches. Thus, the current review highlights the reports, suggesting that probiotics and dietary supplements might be effective and safe therapies for age-related neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.